Korea's Celltrion Gains European Foothold With Latvian Clinical Trial Approval For Herceptin Biosimilar
This article was originally published in The Pink Sheet Daily
Executive Summary
Looking ahead to the expiration of Roche's patent rights for trastuzumab in 2019, Korean firm will start trials in Korea soon and in Latvia later this year.